Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

NCT05736575 | Unknown

• 1 other identifier: CCBDNF
• Study Type: observational
• Target: 66
• Locations: 1 country
• Sites: 1

Brief Summary

A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.

Conditions

Chronic Pain

Keywords

BDNF

Outcome Measures

Primary Outcomes (2)

• BDNF Levels

  Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer \[1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer\], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker.

  3 hours

• Pain Intensity

  Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable"

  3 hours

Study Arms (2)

Chronic Pain Patient

A blood draw is to be performed to analyze peripheral BDNF.

Genetic: BDNF analysis (Elisa KIT)

Asymptomatic subject

A blood draw is to be performed to analyze peripheral BDNF.

Genetic: BDNF analysis (Elisa KIT)

Interventions

BDNF analysis (Elisa KIT) GENETIC

Analysis of peripheral BDNF will be performed

Asymptomatic subject; Chronic Pain Patient

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

subjects will be selected if they have been suffering from musculoskeletal pain (not oncological) for at least 3 months.

You may qualify if:

• males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months
• patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle
• not having received physiotherapy treatment for this same process in the last 3 months.
• ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.

You may not qualify if:

• Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Sponsors & Collaborators

• Universidad Autonoma de Madrid: lead
• Universidad Rey Juan Carlos: collaborator

Study Sites (1)

Irf Cseuls

Madrid, 28053, Spain

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

BDNF levels will be measured through a blood sample taken by a nurse and analysed by a biochemist. Blood collection has been chosen over saliva analysis because the former has been shown to be the most reliable method for measuring this neurotrophin at the peripheral level.

MeSH Terms

Conditions

Chronic Pain

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Raúl Ferrer, PhD

CONTACT

+34655412476; raul.ferrer@lasallecampus.es

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 9, 2023
• First Posted: February 21, 2023
• Study Start: May 15, 2023
• Primary Completion: February 28, 2024
• Study Completion: December 30, 2024
• Last Updated: November 30, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)